drugset / Trial / NCT03345342

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342

Phase 3 Completed 841 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).

Timeline

Start
2017-11-20
Primary completion
2020-05-08
Completion
2020-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 350 mg Intramuscular
Subject paliperidone palmitate Unknown 525 mg Intramuscular
Subject paliperidone palmitate Unknown 700 mg Intramuscular
Subject paliperidone palmitate Unknown 1000 mg Intramuscular
Background PP1M Unknown 50 mg Intramuscular
Background PP1M Unknown 100 mg Intramuscular
Background PP1M Unknown 150 mg Intramuscular

Indications